tert-butyl (2S,3R,4R)-4,5-diacetyloxy-2-amino-3-methylpentanoate | 1537917-85-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: tert-butyl (2S,3R,4R)-4,5-diacetyloxy-2-amino-3-methylpentanoate
• CAS: 1537917-85-3
• 化学式: C₁₄H₂₅NO₆
• 分子量: 303.356
• InChiKey: SVYIDDYYJFBXSO-UWJYBYFXSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  21
• 可旋转键数：
  10
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.79
• 拓扑面积：
  105
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  1‐(tert‐butyl) 4‐methyl L‐aspartate 在 盐酸 、 4-二甲氨基吡啶 、 potassium phosphate 、 lead(II) nitrate 、 草酰氯 、 palladium 10% on activated carbon 、 AD-mix-β 、 水 、 氢气 、 sodium hydride 、 二异丁基氢化铝 、 溶剂黄146 、 二甲基亚砜 、 lithium hexamethyldisilazane 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 甲醇 、 乙醇 、 正己烷 、 二氯甲烷 、 乙腈 、 叔丁醇 为溶剂， 反应 156.75h， 生成 tert-butyl (2S,3R,4R)-4,5-diacetyloxy-2-amino-3-methylpentanoate 、 (2S,3R,4S)-4-amino-5-(tert-butoxy)-3-methyl-5-oxopentane-1,2-diyl diacetate
  参考文献：
  名称：

  [EN] METHODS FOR SYNTHESIZING AMATOXIN BUILDING BLOCK AND AMATOXINS
  [FR] PROCÉDÉS PERMETTANT DE SYNTHÉTISER UN ÉLÉMENT CONSTITUTIF D'AMATOXINE ET DES AMATOXINES

  摘要：

  这项发明涉及一种合成γ，δ-双羟异亮氨酸1（CAS号55399-94-5）的新方法，作为合成鹅膏毒素的构建模块，并提供了利用该构建模块合成鹅膏毒素的新方法。

  公开号：

  WO2014009025A1

文献信息

• Methods for synthesizing amatoxin building block and amatoxins
  申请人：Heidelberg Pharma GmbH

  公开号：EP2684865A1

  公开（公告）日：2014-01-15

  The invention relates to novel methods for synthesizing a synthon for γ,δ-dihydroxyisoleucine 1 (CAS No. 55399-94-5] as building block for the synthesis of amatoxins, and for novel methods for synthesizing amatoxins using such building block.

  这项发明涉及一种合成γ,δ-二羟异亮氨酸1（CAS编号55399-94-5）合成子的新方法，作为合成α毒素的构建模块，并涉及使用该构建模块合成α毒素的新方法。
• METHODS FOR SYNTHESIZING AMATOXIN BUILDING BLOCK AND AMATOXINS
  申请人：Heidelberg Pharma GmbH

  公开号：EP2872479B1

  公开（公告）日：2016-06-08
• AMATOXIN ANTIBODY-DRUG CONJUGATES AND USES THEREOF
  申请人：Magenta Therapeutics, Inc.

  公开号：US20200407440A1

  公开（公告）日：2020-12-31

  Amatoxins, as well as antibody-drug conjugates (ADCs) comprising an amatoxin are provided, as well as compositions and methods of using the same. The compositions and methods provided herein can also be used to prepare a patient for hematopoietic stem cell transplant therapy and to improve the engraftment of hematopoietic stem cell transplants by selectively depleting endogenous hematopoietic stem cells prior to the transplant procedure. Methods and compositions for the treatment of various hematopoietic diseases, metabolic disorders, cancers, and autoimmune diseases, as well as prevention of graft-versus-host-disease (GVHD), are provided.
• US9676702B2
  申请人：——

  公开号：US9676702B2

  公开（公告）日：2017-06-13
• [EN] AMATOXIN ANTIBODY-DRUG CONJUGATES AND USES THEREOF<br/>[FR] CONJUGUÉS ANTICORPS-MÉDICAMENTS D'AMATOXINE ET LEURS UTILISATIONS
  申请人：HEIDELBERG PHARMA RES GMBH

  公开号：WO2020216947A1

  公开（公告）日：2020-10-29

  Amatoxins, as well as antibody-drug conjugates (ADCs) comprising an amatoxin are provided, as well as compositions and methods of using the same. The compositions and methods provided herein can be used for cancer therapy. They can also be used to prepare a patient for hematopoietic stem cell transplant therapy and to improve the engraftment of hematopoietic stem cell transplants by selectively depleting endogenous hematopoietic stem cells prior to the transplant procedure. Methods and compositions for the treatment of various hematopoietic diseases, metabolic disorders, cancers, and autoimmune diseases, as well as prevention of graft-versus-host-disease (GVHD), are provided.